The European HealthTech and MedTech M&A landscape in 2026 is poised for significant strategic acceleration, marking a transition from cautious, volume-driven dealmaking to high-value, transformative transactions. Deal flow is consolidating toward fewer but substantially larger deals, with market participants prioritising scalable technologies with robust clinical validation and AI integration capabilities.

This report provides an exhaustive analysis of the leading boutique M&A investment bankers advising European Digital Health, HealthTech and MedTech founders. It challenges the traditional "league table" hierarchy, positing that for high-growth, innovation-led companies, specialized sector expertise and deep industrial connectivity often outweigh the balance sheet capabilities of global bulge bracket firms. The analysis distinguishes between the "Industrial MedTech" and "Digit